Cytokines in Host Defense Against Pneumonia

Journal of Investigative Medicine

Volumn 45, Issue 6, 1997, Pages 335-345

  Standiford, Theodore J ^a,b   Huffnagle, Gary B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COLONY STIMULATING FACTOR; CYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; HUMAN; IMMUNOLOGY; LUNG; PHYSIOLOGY; PNEUMONIA; REVIEW;

ANIMALS; CHEMOKINES; COLONY-STIMULATING FACTORS; CYTOKINES; HUMANS; INTERFERON TYPE II; LUNG; PNEUMONIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031203695     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Mandell GL, Douglas RG, Bennett JE. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1990:2340.
2. Wunderink R. Ventilator-associated pneumonia. Failure to respond to antibiotic therapy. Clin Chest Med 1995;16:173-93.
3. Nelson S, Mason C, Pierce A. Pathophysiology of pneumonia. Clin Chest Med 1995;16:1-12.
4. Toews GB, Gross GN, Pierce AK. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 1979;120:559-66.
5. Paul W. Fundamental immunology. New York: Raven Press, 1993:1490.
6. Thomson A. The cytokine handbook. London: Academic Press, 1994:615.
7. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993;21:S447-63.
8. Le J, Vilcek J. Tumor necrosis factor and interleukin-1: cytokines with multiple overlapping biological activites. Lab Invest 1987;56:234-48.
9. Shalaby MR, Espevik T, Rice GC, Ammann AJ, Figari IS, Ranges GE, Palladino MA. The involvement of human tumor necrosis factors-alpha and beta in the mixed lymphocyte reaction. J Immunol 1988;141:499-503.
10. Yokota S, Geppert TD, Lipsky PE. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha. J Immunol 1988;140:531-6.
11. Zucali JR, Elfenbein GJ, Barth KC, Dinarello CA. Effects of human interleukin-1 and human tumor necrosis factor on human T lymphocyte colony formation. J Clin Invest 1987;80:772-7.
12. Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF): induction of the TNF receptors on human T cells and TNF-mediated enhancement of T cell responses. J Immunol 1987;138:1786-90.
13. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor-alpha. J Exp Med 1987;166:991-8.
14. Dehoux M, Boutten A, Ostinelli J, Seta N, Dombret M, Crestani B, Deschenes M, Trouillet J, Aubier M. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710-6.
15. Laichalk L, Kunkel S, Streiter R, Danforth J, Bailie M, Standiford T. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 1996;64:5211-8.
16. Gosselin D, DeSanctis J, Boule M, Skamene E, Matouk C, Radzioch D. Role of tumor necrosis factor-alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995;63:3272-8.
17. Brieland J, Remick D, Freeman P, Hurley M, Fantone J, Engleberg N. In vivo regulation of replicative Legionella pneumophila lung infection by endogenous tumor necrosis factor-alpha and nitric oxide. Infect Immun 1995;63:3253-8.
18. Nelson S, Bagby G, Summer W. Anti-tumor necrosis factor-alpha antibody suppresses pulmonary antibacterial defenses. Am Rev Respir Dis 1991;143S:393.
19. Kolls J, Beck J, Nelson S, Summer W, Shellito J. Alveolar macrophages release of tumor necrosis factor during murine Pneumocystis carinii pneumonia. Am J Respir Cell Mol Biol 1993;8:370-6.
20. Orme IM. Immune responses in animal models. Curr Top Microbiol Immunol 1996;215:181-96.
21. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, Kunkel SL, Strieter RM. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996;157:4529-36.
22. Huffnagle GB, Chen GH, Curtis JL, McDonald RA, Strieter RM, Toews GB. Downregulation of the afferent phase of T cell-mediated immunity and pulmonary inflammation by a high melanin-producing strain of C neoformans. J Immunol 1995;155:3507-16.
23. Aguirre K, Havell EA, Gibson GW, Johnson LL. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 1995;63:1725-31.
24. Collins HL, Bancroft GJ. Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol 1992;22:1447-54.
25. Vecchiarelli A, Retini C, Pietrella D, Monari C, Tascini C, Beccari T, Kozel TR. Downregulation by cryptococcal polysaccharide of tumor necrosis factor-alpha and interleukin-1 beta secretion from human monocytes. Infect Immun 1995;63:2919-23.
26. Levitz SM, Tabuni A, Kornfeld H, Reardon CC, Golenbock DT. Production of tumor necrosis factor-alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect Immun 1994;62:1975-81.
27. Naslund PK, Miller WC, Granger DL. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun 1995;63:1298-304.
28. Kolls J, Nelson S, Summer W. Recombinant cytokines and pulmonary host defense. Am J Med Sci 1993;306:330-5.
29. Nelson S. Overview of granulocyte colony-stimulating factor in bacterial infections in the non-neutropenic host. Clin Infect Dis 1991;143S:398-410.
30. Chen GH, Curtis JL, Mody CH, Christensen PJ, Armstrong LR, Toews GB. Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J Immunol 1994;152:724-34.
31. Lister P, Gentry M, Preheim L. Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993;168:922-6.
32. Preheim L, Snitily M, Gentry M. Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 1996;174:225-8.
33. Smith W, Sumnicht G, Sharpe R, Samuelson D, Millard F. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995;86:1301-9.
34. Blanchard DK, Michelini NM, Pearson CA, McMillen S, Djeu JY. Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M intracellulare: activation of bactericidal activity by GM-CSF. Infect Immun 1991;59:2396-402.
35. Denis M. Tumor necrosis factor and granulocyte-macrophage colony-stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991;49:380-7.
36. Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 1990;48:67-73.
37. Levitz SM. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect Immun 1991;59:3393-7.
38. Mandujano J, D'Souza N, Nelson S, Summer W, Beckerman R, Shellito J. Granulocyte-macrophage colony-stimulating factor and Pneumocystis carinii pneumonia in mice. Am J Respir Crit Care Med 1995;151:1233-8.
39. Jenson W, Rose R, Wasserman A, Kalb T, Anton K, Remold H. In vitro activation of the antibacterial activity of human pulmonary macrophages by recombinant gamma interferon. J Infect Dis 1987;155:574-7.
40. Hoag KA, Street NE, Huffnagle GB, Lipscomb MF. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol 1995;13:487-95.
41. Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 1994;55:35-42.
42. Lovchik JA, Lyons CR, Lipscomb MF. A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol 1995;13:116-24.
43. Mody CH, Tyler CL, Sitrin RG, Jackson C, Toews GB. Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity. Am J Respir Cell Mol Biol 1991;5:19-25.
44. Beck J, Liggitt H, Brunette E, Fuchs H, Shellito J, Debs R. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991;59:3859-62.
45. Skerrett S, Martin T. Intratracheal interferon-gamma augments pulmonary defenses in experimental legionellosis. Am J Respir Crit Care Med 1994;149:50-8.
46. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 1991;9:617-47.
47. Huffnagle GB, Toews GB. Mechanisms of macrophage recruitment into infected lungs. In: Lipscomb MF, Russell S, eds. Lung macrophages and dendritic cells. New York: Marcel Dekker, Inc., 1996:373-407.
48. Huffnagle GB, Strieter RM, Kunkel SL, Toews GB, Standiford TJ. The role of chemokines in pneumonia. In: Koch AE, Strieter RM, eds. Chemokines in disease. Austin: R.G. Landes Company, 1996:151-68.
49. Greenberger M, Strieter RM, Kunkel SL, Danforth J, Laichalk L, McGillicuddy D, Standiford TJ. Neutralization of MIP-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 1996;173:159-65.
50. Huffnagle GB, Strieter RM, Standiford TJ, McDonald RA, Burdick MD, Kunkel SL, Toews GB. The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection. J Immunol 1995;155:4790-7.
51. Howard M, O'Garra A, Ishida H, Malefyt R, De Vries J. Biological properties of interleukin-10. J Clin Immunol 1992;12:239-47.
52. Chehimi J, Trinchieri G. Interleukin-12: a bridge between innate resistence and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994;14:149-59.
53. Brunde M. Interleukin-12. J Leukoc Biol 1994;55:280-8.
54. Gazzinelli R, Hieny S, Wynn T, Wolf S, Sher A. Interleukin-12 is required for the T-lymphocyte-independent induction of interferon-gamma by an intracellular parasite and induces resistance in T-cell deficient hosts. Proc Natl Acad Sci USA 1993;90:6115-9.
55. Heinzel F, Schoenhaut D, Rerko R, Rosser L, Gately M. Recombinant interleukin-12 cures mice infected with Leischmania major. J Exp Med 1993;177:1505-9.
56. Flynn J, Goldstein M, Triebold K, Sypek J, Wolf S, Bloom B. Interluekin-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995;155:2515-24.
57. Stevenson M, Tam M, Wolfeand S, Sher A. Interleukin-12-induced protection against blood-stage plasmodium chabaudi requires IFN-γ and TNF-α and occurs via a nitric oxide-dependent mechanism. J Immunol 1995;155:2545-56.
58. Wagner R, Steinberg H, Brown J, Czuprynski C. Recombinant interleukin-12 enhances resistance to mice to Listeria monocytogenes infection. Microb Pathog 1994;17:175-86.
59. Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, Orme IM. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995;84:423-32.
60. Zhou P, Sieve MC, Bennett J, Kwon-Chung KJ, Tewari RP, Gazzinelli RT, Sher A, Seder RA. Interleukin-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol 1995;155:785-95.
61. Kawakami K, Tohyama M, Xie Q, Saito A. Interleukin-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996;104:208-14.
62. Greenberger M, Kunkel SL, Strieter RM, Lukacs N, Bramson J, Gauldie J, Graham F, Hitt M, Danforth J, Standiford TJ. Interleukin-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996;157:3006-12.
63. Laichalk L, Danforth J, Standiford T. Interleukin-10 inhibits neutrophil phagocytic and bacterial activity. FEMS Immunol Med Microbiol 1996;15:181-7.
64. Oswald I, Wynn T, Sher A. Interleukin-10 inhibits macrophage microbicidal activity by blocking endogenous production of tumor necrosis factor-α required as a costimulatory factor for interferon-gamma-induced activation. Proc Natl Acad Sci USA 1992;89:8676-80.
65. Kasama T, Strieter R, Lukacs NW, Burdick MD, Kunkel SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-69.
66. Cassatella M, Meda L, Bonora S, Ceska M, Constantin G. Interleukin-10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccaride. J Exp Med 1993;178:2207-11.
67. Rolph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min H, In L. Interleukin-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808-14.
68. Standiford T, Strieter R, Lukacs N, Kunkel S. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995;155:2222-9.
69. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin-10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205-8.
70. Greenberger M, Strieter R, Kunkel S, Danforth J, Goodman R, Standiford T. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-9.
71. van der Poll T, Marchant A, Keogh C, Goldman M, Lowry S. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
72. Bermudez LE, Champsi J. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administrationof anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun 1993;61:3093-7.
73. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 1996;64:2846-9.
74. Davies J. Inactivation of antibiotics and dissemination of resistance genes. Science 1994;264:375-82.
75. Nelson S, Farkas S, Fitheringham N, Ho H, Marrie T, Movahhed H. Filgrastim in the treatment of hospitalized patients with community-acquired pneumonia (CAP). Am J Resp Crit Care Med 1996;153:A535.
76. Interleukin-12 deaths: explanation and the puzzle [news and comment]. Science 1995;270:908.
77. Tracey K, Beutler B, Lowry S, Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
78. Bramson J, Hitt M, Gallichan W, Rosenthal K, Gauldie J, Graham F. Construction and characterization of an adenovirus expressing IL-12. Hum Gene Ther 1995;7:333-40.
79. Kolls J, Lei D, Nelson S, Summer W, Greenberg S, Beutler B. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 1995;171:570-5.